Pliva

Pliva. It is a major European pharmaceutical company, historically headquartered in Zagreb and now operating as a key subsidiary of the global giant Teva Pharmaceutical Industries. Founded in the early 20th century, it grew from a local enterprise into an internationally recognized leader in the development and production of generic drugs and active pharmaceutical ingredients. The company is particularly noted for its pioneering discovery of the widely used antibiotic azithromycin.

History

The company's origins trace back to 1921, when it was established as a small laboratory in Zagreb, then part of the Kingdom of Serbs, Croats and Slovenes. Its early growth was supported by the post-World War II industrialization of the Socialist Federal Republic of Yugoslavia, allowing it to expand its manufacturing capabilities significantly. A pivotal moment in its history occurred in the 1980s, when its research team, led by Slobodan Đokić, discovered the molecule azithromycin, which was later licensed to the American corporation Pfizer. Following the dissolution of Yugoslavia and the Croatian War of Independence, the firm was privatized and transformed into a publicly traded company on the Zagreb Stock Exchange. Its international profile was cemented in 2006 when it was acquired by the Israeli multinational Teva Pharmaceutical Industries in one of the largest corporate takeovers in Central and Eastern Europe.

Products and operations

The company's core business encompasses a broad portfolio of generic drugs across numerous therapeutic areas, including antibiotics, central nervous system agents, and cardiovascular disease treatments. It operates extensive manufacturing facilities, most notably its large production complex in Zagreb, which produces both finished dosage forms and bulk active pharmaceutical ingredients (APIs). As part of Teva Pharmaceutical Industries, its operations are integrated into a global supply chain, serving markets throughout Europe, North America, and beyond. Key historical products, besides the famed azithromycin (marketed by Pfizer as Zithromax), include other anti-infectives and a range of over-the-counter drugs.

Research and development

The organization has a strong legacy in pharmaceutical research and development, with its most celebrated achievement being the discovery and patenting of azithromycin in the 1980s. This breakthrough emerged from its research facilities in Zagreb and involved significant collaboration with international partners, including the University of Zagreb. While its R&D focus shifted towards the development of generic drugs and biosimilars following its acquisition by Teva Pharmaceutical Industries, it maintains important development activities related to formulation technology and process optimization for APIs. The company's historical contributions to medicinal chemistry have been recognized by institutions like the Croatian Academy of Sciences and Arts.

Corporate affairs

As a subsidiary of Teva Pharmaceutical Industries, the company's strategic direction is aligned with its parent's global objectives. Its headquarters and main operations remain located in Zagreb, where it is one of the largest exporters and a significant employer in the Croatian economy. The firm has been involved in various legal and regulatory matters common to the pharmaceutical industry, including patent litigations and compliance with standards set by the European Medicines Agency and the U.S. Food and Drug Administration. Its corporate governance has evolved through its history as a state-owned enterprise, a publicly traded company on the Zagreb Stock Exchange, and finally as part of a multinational conglomerate.

Impact and recognition

The discovery of azithromycin represents the company's most profound impact on global medicine, providing a critical tool in the treatment of infectious diseases worldwide through Pfizer's Zithromax. Within Croatia, it is regarded as a flagship of national industry and a symbol of scientific achievement, contributing substantially to the country's export economy. The company and its scientists have received numerous awards, including the prestigious National Medal of Technology nomination in the United States for the azithromycin discovery. It is frequently cited in academic and industry literature as a prime example of successful pharmaceutical innovation emerging from Central Europe.

Category:Pharmaceutical companies of Croatia Category:Companies based in Zagreb Category:Generic drug manufacturers